Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost.

被引：1
|
作者：
Moskovitz, Mor Tal
Matthews, Priscilla M.
Pavel, Alexandra M.
Xu, Wei
Bradbury, Penelope Ann
Liu, Geoffrey
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
174
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
    Mellemgaard, Anders
    Engel-Norregaard, Lotte
    Andersen, Mads Hald
    Zocca, Mai-Britt
    Svane, Inge Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] High Grade Toxicity and Response to PD-1 Axis Inhibitors in Advanced NSCLC
    Moskovitz, M.
    Agbarya, A.
    Wollner, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S640 - S641
  • [23] Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC : A Retrospective Study
    Chen, Tianxiang
    Ning, Junwei
    Campisi, Alessio
    Dell'Amore, Andrea
    Ciarrocchi, Angelo Paolo
    Li, Ziming
    Song, Liwei
    Huang, Jia
    Yang, Yunhai
    Stella, Franco
    Luo, Qingquan
    ANNALS OF THORACIC SURGERY, 2022, 113 (03): : 993 - 999
  • [24] Impact of cachexia in advanced NSCLC patients treated with PD-1 inhibitor
    Jo, Hitomi
    Horinouchi, Hidehito
    Yagishita, Shigehiro
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [25] Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
    Martini, Dylan J.
    Lalani, Aly-Khan A.
    Bosse, Dominick
    Steinharter, John A.
    Harshman, Lauren C.
    Hodi, F. Stephen
    Ott, Patrick A.
    Choueiri, Toni K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [26] Patterns of Disease Progression for Stage IV NSCLC While on PD-1 Directed Therapy as Compared to Standard Chemotherapy
    Chatwal, Monica S.
    Ernani, Vinicius
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Pillai, Rathi N.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S644 - S644
  • [27] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
  • [28] Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC
    Matsuzawa, R.
    Morise, M.
    Tanaka, I.
    Koyama, J.
    Kimura, T.
    Kondoh, Y.
    Hase, T.
    Sakamoto, K.
    Hashimoto, N.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S716 - S716
  • [29] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    Rothschild, S. I.
    Leger, P.
    Castellanos, E. L.
    Pillai, R. N.
    York, S. J.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
    Malhotra, Jyoti
    Huang, Amy
    Amini, Arya
    Lee, Percy
    CANCERS, 2024, 16 (21)
12345